Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
BörsenkürzelAVR
Name des UnternehmensAnteris Technologies Global Corp
IPO-datumDec 13, 2024
CEOMr. Wayne G. Paterson
Anzahl der mitarbeiter136
WertpapierartOrdinary Share
GeschäftsjahresendeDec 13
Addresse860 Blue Gentian Road
StadtEAGAN
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl55121
Telefon16514930606
Websitehttps://anteristech.com/
BörsenkürzelAVR
IPO-datumDec 13, 2024
CEOMr. Wayne G. Paterson
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten